Targeting LAG-3 to Potentiate Antitumor Immune Activity: Expert Guidance on Molecular Function and Clinical Application

Watch this on-demand webcast of a live webinar to gain expert insights on the safety and efficacy of anti–LAG-3 immunotherapies in the management of various solid tumors.

Evan J. Lipson, MD Tian Zhang, MD, MHS Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: April 20, 2022 Expired: April 19, 2023

In this commentary, Dr. Evan Lipson reviews LAG-3 as a therapeutic target and discusses evidence from the RELATIVITY-047 trial of the combination of the anti–LAG-3 antibody relatlimab plus nivolumab as first-line therapy in advanced melanoma.

Evan J. Lipson, MD Released: March 21, 2022

Download these slides from a live workshop series to learn more about LAG-3 as the latest validated immune checkpoint therapeutic target, evidence on the first approved LAG-3 therapy, relatlimab, and the many investigational agents targeting LAG-3 across multiple tumor types.

Evan J. Lipson, MD Tian Zhang, MD, MHS Released: March 23, 2022

Download these slides explaining the mechanism of action of LAG-3.

Download this PDF summary resource to learn more about LAG-3 as the latest validated immune checkpoint therapeutic target, the first approved LAG-3 therapy relatlimab, and investigational agents targeting LAG-3 across multiple tumor types.

Krista M. Rubin, MS, RN, FNP-BC Released: March 23, 2022